Washington University in St. Louis

Washington University Open Scholarship
Spring 2018

Washington University
Senior Honors Thesis Abstracts

Spring 2018

Analysis of Cyclophilin A Levels in Subarachnoid Hemorrhage
Patients
Devin Patel
Washington University in St. Louis

Follow this and additional works at: https://openscholarship.wustl.edu/wushta_spr2018

Recommended Citation
Patel, Devin, "Analysis of Cyclophilin A Levels in Subarachnoid Hemorrhage Patients" (2018). Spring 2018.
97.
https://openscholarship.wustl.edu/wushta_spr2018/97

This Abstract for College of Arts & Sciences is brought to you for free and open access by the Washington
University
Senior Honors Thesis Abstracts at Washington University Open Scholarship. It has been accepted for inclusion in
Spring 2018 by an authorized administrator of Washington University Open Scholarship. For more information,
please contact digital@wumail.wustl.edu.

Biology

Analysis of Cyclophilin A Levels in
Subarachnoid Hemorrhage Patients
Devin Patel
Mentors: Gregory Zipfel and Itender Singh
Subarachnoid hemorrhage (SAH), a unique form of hemorrhagic stroke, remains
a serious health problem with a 30% mortality rate in the United States. Of those
surviving the initial hemorrhage, more than half deteriorate in the days following SAH
due to delayed cerebral ischemia (DCI) and early brain injury (EBI). The predominant
vascular deficit leading to EBI is blood-brain barrier (BBB) disruption, along with the
release of cytotoxic agents and inflammatory mediators. Recently, a causal link between
metalloprotease 9 (MMP9) and EBI after SAH has been suggested in rodent studies.
A correlation between serum MMP9 levels and vasospasm in human SAH has also
been noted. While a major contributing role of MMP9 in SAH-induced brain injury
is rapidly being established, the upstream molecular events leading to its upregulation
and the downstream molecular events by which it causes EBI are poorly understood.
Cyclophilin A (CypA) is a proinflammatory molecule that is known to drive MMP9
expression via the transcription factor NF-κ B p65. Previously we discovered that CypA
plays a causal role in AD-induced cerebrovascular deficits, including APOE4-linked BBB
disruption and CBF deficits. CypA is secreted from cells in response to inflammatory
stimuli, such as hypoxia and oxidative stress. Whether CypA plays a role in EBI and DCI
following SAH, however, is not known. Our key goal is to identify if CypA levels increase
in SAH patients and are involved in DCI and EBI. We hypothesize that reactive oxygen
species (ROS) released by hypoperfusion and the degradation of hemoglobin stimulate
the secretion of significant amounts of CypA, which contributes to neurological and
cerebral dysfunction. Furthermore, we hypothesize a prevalent role of CypA in DCI,
EBI, and poor clinical outcome and therefore hope to identify CypA as a therapeutically
targetable molecule.
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